CoChat

A retinoic acid-enhanced, multicellular human blood-brain barrier model derived from stem cell sources

Open access

The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.

Abstract

Blood-brain barrier (BBB) models are often used to investigate BBB function and screen brain-penetrating therapeutics, but it has been difficult to construct a human model that possesses an optimal BBB phenotype and is readily scalable. To address this challenge, we developed a human in vitro BBB model comprising brain microvascular endothelial cells (BMECs), pericytes, astrocytes and neurons derived from renewable cell sources. First, retinoic acid (RA) was used to substantially enhance BBB phenotypes in human pluripotent stem cell (hPSC)-derived BMECs, particularly through adherens junction, tight junction, and multidrug resistance protein regulation. RA-treated hPSC-derived BMECs were subsequently co-cultured with primary human brain pericytes and human astrocytes and neurons derived from human neural progenitor cells (NPCs) to yield a fully human BBB model that possessed significant tightness as measured by transendothelial electrical resistance (~5,000 Ωxcm(2)). Overall, this scalable human BBB model may enable a wide range of neuroscience studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/srep04160

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 RA treatment modulates BBB properties in differentiating IMR90-4 iPSCs. 10 μM RA was used for all experiments except those in panel D. (A) All data were collected from mixed, differentiating cultures after 48 h of EC medium treatment with or without RA. (B) Expression of PECAM-1, GLUT-1, occludin, claudin-5, and VE-cadherin. DAPI overlay is shown for VE-cadherin in the control culture. (C) Representative flow cytometry histograms of VE-cadherin expression in control and RA-treated cultures. Mean ± S.D. of VE-cadherin+ cells due to RA treatment was calculated from seven biological replicates where a biological replicate is defined as an independent hPSC differentiation experiment. (D) Western blots after treatment with 0, 1, or 10 μM RA. (E) Representative flow cytometry dot plots of GLUT-1 and PECAM-1 populations in control and RA-treated differentiating cultures. Red dots, PECAM-1+/GLUT-1+ cells; blue dots, PECAM-1+/GLUT-1− cells; green dots, PECAM-1−/GLUT-1− cells. Statistical significance listed in the Results section was calculated on three independent biological replicates using the student's unpaired t-test. (F) Total cell number was quantified by counting trypsin-dissociated cells. Control cells, N = 18; RA-treated cells, N = 7. Data are represented as mean ± S.D. with statistical significance calculated using the student's unpaired t-test.
Figure 1 RA treatment modulates BBB properties in differentiating IMR90-4 iPSCs. 10 μM RA was used for all experiments except those in panel D. (A) All data were collected from mixed, differentiating cultures after 48 h of EC medium treatment with or without RA. (B) Expression of PECAM-1, GLUT-1, occludin, claudin-5, and VE-cadherin. DAPI overlay is shown for VE-cadherin in the control culture. (C) Representative flow cytometry histograms of VE-cadherin expression in control and RA-treated cultures. Mean ± S.D. of VE-cadherin+ cells due to RA treatment was calculated from seven biological replicates where a biological replicate is defined as an independent hPSC differentiation experiment. (D) Western blots after treatment with 0, 1, or 10 μM RA. (E) Representative flow cytometry dot plots of GLUT-1 and PECAM-1 populations in control and RA-treated differentiating cultures. Red dots, PECAM-1+/GLUT-1+ cells; blue dots, PECAM-1+/GLUT-1− cells; green dots, PECAM-1−/GLUT-1− cells. Statistical significance listed in the Results section was calculated on three independent biological replicates using the student's unpaired t-test. (F) Total cell number was quantified by counting trypsin-dissociated cells. Control cells, N = 18; RA-treated cells, N = 7. Data are represented as mean ± S.D. with statistical significance calculated using the student's unpaired t-test.CC BY-NC-ND · PubMed Central
Figure 2 Passive and active barrier properties in purified RA-treated IMR90-4-derived BMECs. 10 μM RA was used for all experiments. (A) Analysis was conducted on purified BMECs in 12-well plates or Transwell filters with or without RA treatment. (B) Flow cytometric purity analysis of VE-cadherin, claudin-5, and occludin expressing cells in purified RA-treated BMEC preparations. (C) Evaluation of tight junction continuity for control and RA-treated BMECs. Frayed tight junction strands (arrowheads) were quantified. (D) TEER values for control and RA-treated BMECs. Statistical significance was calculated using the student's unpaired t-test. Mean ± S.D. was calculated across biological replicates (see Table 1 for full details). (E) Changes in efflux transporter gene expression by qPCR. ABCB1, ABCG2, ABCC1, ABCC2, ABCC5, and STRA6 were upregulated due to RA treatment (positive change in ΔΔCt). ABCC4 and SLC2A1 were unaffected by RA. Mean ± S.D. were calculated from triplicate reactions and results are representative of two biological replicates. Statistical significance was calculated using the student's unpaired t-test (*, p < 0.01; **, p < 0.005). (F) Immunocytochemical detection of p-glycoprotein, BCRP, and MRP1 in RA-treated BMECs. DAPI nuclear stain is overlaid in blue. (G) Efflux transporter inhibition in control or RA-treated BMECs. All inhibitor-treated samples (control or RA-treated) were independently normalized to the corresponding non-inhibitor-treated samples. Statistical significance was calculated using the student's unpaired t-test and is discussed in the Results section. Only normalized DCFDA uptake in the presence of MK 571 was significantly different between control and RA-treated BMECs (p < 0.005).
Figure 2 Passive and active barrier properties in purified RA-treated IMR90-4-derived BMECs. 10 μM RA was used for all experiments. (A) Analysis was conducted on purified BMECs in 12-well plates or Transwell filters with or without RA treatment. (B) Flow cytometric purity analysis of VE-cadherin, claudin-5, and occludin expressing cells in purified RA-treated BMEC preparations. (C) Evaluation of tight junction continuity for control and RA-treated BMECs. Frayed tight junction strands (arrowheads) were quantified. (D) TEER values for control and RA-treated BMECs. Statistical significance was calculated using the student's unpaired t-test. Mean ± S.D. was calculated across biological replicates (see Table 1 for full details). (E) Changes in efflux transporter gene expression by qPCR. ABCB1, ABCG2, ABCC1, ABCC2, ABCC5, and STRA6 were upregulated due to RA treatment (positive change in ΔΔCt). ABCC4 and SLC2A1 were unaffected by RA. Mean ± S.D. were calculated from triplicate reactions and results are representative of two biological replicates. Statistical significance was calculated using the student's unpaired t-test (*, p < 0.01; **, p < 0.005). (F) Immunocytochemical detection of p-glycoprotein, BCRP, and MRP1 in RA-treated BMECs. DAPI nuclear stain is overlaid in blue. (G) Efflux transporter inhibition in control or RA-treated BMECs. All inhibitor-treated samples (control or RA-treated) were independently normalized to the corresponding non-inhibitor-treated samples. Statistical significance was calculated using the student's unpaired t-test and is discussed in the Results section. Only normalized DCFDA uptake in the presence of MK 571 was significantly different between control and RA-treated BMECs (p < 0.005).CC BY-NC-ND · PubMed Central
Figure 3 Effects of pericyte and differentiated NPC co-culture on TEER induction in IMR90-4-derived BMECs. (A) Description of co-culture schemes. For all experiments, IMR90-4-derived BMECs were purified into standard EC medium for the subculture phase and switched to NPC medium for the co-culture phase. (B) NPCs were differentiated for 9, 12, or 15 days prior to co-culture with IMR90-4-derived BMECs (Scheme MNPC). Monocultured IMR90-4-derived BMECs were used as a negative control (Scheme MM). (C) TEER measured on IMR90-4-derived BMECs in co-culture with pericytes and differentiated NPCs (Schemes MP, MNPC, and PNPC). *, p < 0.01 between Schemes MP and MNPC; **, p < 0.02 between Schemes MNPC and PNPC. (D) 10 μM RA treatment prior to pericyte and differentiated NPC co-culture. TEER for RA-treated BMECs was measured upon confluence (0 h) and after 24 hours (24 h). The increase in baseline TEER at confluence for Schemes PP and PNPC compared to Schemes MM, MP, and MNPC was reproducible across six biological experiments. For all experiments, triplicate filters were used to calculate mean ± S.D. and statistical significance was calculated using the student's unpaired t-test.
Figure 3 Effects of pericyte and differentiated NPC co-culture on TEER induction in IMR90-4-derived BMECs. (A) Description of co-culture schemes. For all experiments, IMR90-4-derived BMECs were purified into standard EC medium for the subculture phase and switched to NPC medium for the co-culture phase. (B) NPCs were differentiated for 9, 12, or 15 days prior to co-culture with IMR90-4-derived BMECs (Scheme MNPC). Monocultured IMR90-4-derived BMECs were used as a negative control (Scheme MM). (C) TEER measured on IMR90-4-derived BMECs in co-culture with pericytes and differentiated NPCs (Schemes MP, MNPC, and PNPC). *, p < 0.01 between Schemes MP and MNPC; **, p < 0.02 between Schemes MNPC and PNPC. (D) 10 μM RA treatment prior to pericyte and differentiated NPC co-culture. TEER for RA-treated BMECs was measured upon confluence (0 h) and after 24 hours (24 h). The increase in baseline TEER at confluence for Schemes PP and PNPC compared to Schemes MM, MP, and MNPC was reproducible across six biological experiments. For all experiments, triplicate filters were used to calculate mean ± S.D. and statistical significance was calculated using the student's unpaired t-test.CC BY-NC-ND · PubMed Central
Figure 4 Optimized co-culture of IMR90-4-derived RA-treated BMECs in modified EC medium. 10 μM RA was used for all experiments. (A) BMECs were purified into standard EC medium for the subculture phase and switched to modified EC medium for the co-culture phase. Scheme FF utilized non-neural fibroblasts as a cellular control. (B) Time course of TEER induction. Data is presented as mean ± S.D. calculated from triplicate filters. The baseline TEER increase at 0 h due to pericytes relative to fibroblasts was confirmed across three biological replicates. (C) Biological replicates for Scheme PNPC. NPC differentiation time ranged from 9-24 days. Data is presented as mean ± S.D. calculated from triplicate filters. Each bar represents an individual biological experiment. (D) Tight junction fidelity via occludin immunofluorescence was compared in RA-treated BMECs from Scheme MM and Scheme PNPC.
Figure 4 Optimized co-culture of IMR90-4-derived RA-treated BMECs in modified EC medium. 10 μM RA was used for all experiments. (A) BMECs were purified into standard EC medium for the subculture phase and switched to modified EC medium for the co-culture phase. Scheme FF utilized non-neural fibroblasts as a cellular control. (B) Time course of TEER induction. Data is presented as mean ± S.D. calculated from triplicate filters. The baseline TEER increase at 0 h due to pericytes relative to fibroblasts was confirmed across three biological replicates. (C) Biological replicates for Scheme PNPC. NPC differentiation time ranged from 9-24 days. Data is presented as mean ± S.D. calculated from triplicate filters. Each bar represents an individual biological experiment. (D) Tight junction fidelity via occludin immunofluorescence was compared in RA-treated BMECs from Scheme MM and Scheme PNPC.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

Items 201–300 of 547

Metadata

Authors
Lippmann, E. S., Al-Ahmad, A., Azarin, S. M., Palecek, S. P., & Shusta, E. V.
Affiliations
University of Wisconsin–Madison (US)
Corresponding author
  • Palecek, Sean P.
  • Shusta, Eric V.
Venue
Scientific Reports
Published
2014-02-24
Volume
4
Issue
1
Pages
4160-4160
ISSN
2045-2322 (ISSN-L)
OpenAlex
W2042883482
Cited by
508
References
51
Citations by year
2026: 23 · 2025: 39 · 2024: 45 · 2023: 55 · 2022: 56 · 2021: 45 · 2020: 58 · 2019: 54 · 2018: 41 · 2017: 34 · 2016: 26 · 2015: 22 · 2014: 10
FWCI
15.93
Type
journal article
Language
en
Open access
Licence
Locations
  • Scientific Reports (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Science Foundation (NS083688)
  • Cedars-Sinai Medical Center
  • Beijing Municipal Education Commission
  • National Institutes of Health
  • National Institute on Alcohol Abuse and Alcoholism (AA020476, RC4AA020476)
  • National Cancer Institute (P30CA014520)
  • National Institute of General Medical Sciences (T32GM008505)
  • National Institute of Neurological Disorders and Stroke (R01NS083688, NS083688)
Topics
  • Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
Keywords
blood-brain barrier model, retinoic acid, human pluripotent stem cells, brain microvascular endothelial cells, pericytes, astrocytes, neural progenitor cells, tight junctions, adherens junctions, multidrug resistance protein, transendothelial electrical resistance, co-culture
MeSH terms
Astrocytes, Blood-Brain Barrier, Brain, Cell Differentiation, Cells, Cultured, Electric Conductivity, Endothelium, Vascular, Humans, Models, Biological, Neurons, Tretinoin, Coculture Techniques, Pericytes, Pluripotent Stem Cells, Neural Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.